Substances_alcohol

Alcohol Addiction: Signs, Treatment, and Recovery in New Jersey

By NJ Addiction Centers Editorial Team | Last reviewed: | 24 min read Clinically Reviewed

Alcohol use disorder (AUD) is the most common substance use disorder in the United States. According to the National Institute on Alcohol Abuse and Alcoholism (NIAAA), an estimated 28.6 million adults met the criteria for AUD in 2021 — yet fewer than 10 percent received any treatment. In New Jersey, alcohol remains the most frequently cited substance at treatment admission after opioids, and alcohol-related liver disease, motor vehicle fatalities, and emergency department visits continue to place significant strain on the state’s healthcare system. This guide covers how alcohol addiction develops, what treatment involves, why alcohol withdrawal requires medical attention, and what New Jersey-specific resources are available.

Key Takeaways

  • Alcohol use disorder (AUD) is a medical condition defined by the DSM-5, diagnosed based on 11 criteria ranging from impaired control to physical dependence.
  • Alcohol withdrawal can be a medical emergency. Unlike opioid withdrawal, alcohol withdrawal can cause seizures and delirium tremens (DTs), both of which can be fatal without medical intervention.
  • Treatment for AUD includes medical detox, inpatient and outpatient rehabilitation, behavioral therapy, and FDA-approved medications — naltrexone (ReVia, Vivitrol), acamprosate (Campral), and disulfiram (Antabuse).
  • New Jersey has an extensive network of alcohol treatment programs, including state-funded options, Medicaid-covered services, and private facilities across all 21 counties.
  • Recovery from alcohol addiction is a long-term process. Relapse rates for AUD are comparable to those of other chronic conditions, and ongoing support significantly improves outcomes.
  • According to the NIAAA, approximately one-third of people treated for AUD achieve sustained sobriety, and an additional one-third significantly reduce their drinking.

Understanding Alcohol Addiction

Alcohol use disorder (AUD): A chronic medical condition characterized by an impaired ability to stop or control alcohol use despite adverse social, occupational, or health consequences. The DSM-5 defines AUD on a spectrum from mild (2-3 criteria met) to moderate (4-5 criteria) to severe (6 or more criteria).

Alcoholism — a term still widely used in everyday language — is not precisely the same as AUD, though the terms are often used interchangeably. The shift toward “alcohol use disorder” in clinical settings reflects an effort to define the condition through observable diagnostic criteria rather than cultural or moral framing.

DSM-5 Diagnostic Criteria for AUD

The Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) identifies 11 criteria for alcohol use disorder. A person meeting any two or more of these criteria within a 12-month period may be diagnosed with AUD. The criteria are:

  1. Drinking more or for longer than intended
  2. Wanting to cut down or stop but being unable to
  3. Spending a lot of time drinking or recovering from drinking
  4. Experiencing cravings or strong urges to drink
  5. Drinking interfering with responsibilities at work, school, or home
  6. Continuing to drink despite social or relationship problems caused by alcohol
  7. Giving up important activities because of drinking
  8. Drinking in physically dangerous situations (e.g., driving, swimming)
  9. Continuing to drink despite knowing it is causing or worsening a physical or psychological condition
  10. Needing more alcohol to achieve the same effect (tolerance)
  11. Experiencing withdrawal symptoms when not drinking (or drinking to avoid withdrawal)

Mild AUD involves 2 to 3 criteria. Moderate AUD involves 4 to 5 criteria. Severe AUD involves 6 or more criteria. This spectrum approach replaced the older distinction between “alcohol abuse” and “alcohol dependence” used in the DSM-IV.

How AUD Develops

AUD develops through a combination of genetic, environmental, and behavioral factors. The NIAAA estimates that genetics account for roughly 50 percent of the risk for developing alcohol use disorder, with the remainder influenced by environmental factors such as early exposure, peer behavior, trauma, stress, and the availability of alcohol.

The neurobiology of alcohol addiction involves changes to the brain’s reward, stress, and executive function systems. Chronic alcohol exposure increases the release of dopamine in the brain’s reward circuits, reinforcing drinking behavior. Over time, the brain adapts by downregulating dopamine receptors, which means the person needs more alcohol to experience the same effect (tolerance) and feels less pleasure from activities that previously provided it (anhedonia). Simultaneously, the brain’s stress systems become hyperactive during periods of abstinence, producing anxiety, irritability, and dysphoria that drive further drinking.

The progression from regular drinking to alcohol dependence is not always obvious. Early signs and symptoms of alcohol addiction include increasing tolerance, drinking more or longer than intended, unsuccessful attempts to cut down, spending significant time obtaining or recovering from alcohol, and continued use despite recognizing that it is causing problems.

NJ Alcohol Statistics

In New Jersey, SAMHSA’s National Survey on Drug Use and Health (NSDUH) data indicates that the state’s rates of alcohol use disorder among adults are broadly consistent with national averages. However, certain populations — including young adults ages 18 to 25, individuals with co-occurring mental health conditions, and people with a family history of alcoholism — face elevated risk.

According to the NJ Division of Mental Health and Addiction Services (DMHAS), alcohol was the primary substance for approximately 25 percent of treatment admissions in New Jersey in 2022, second only to heroin/opioids. The NJ Department of Health reports that alcohol-related motor vehicle fatalities account for approximately 25 to 30 percent of all traffic deaths in the state annually. The CDC’s Behavioral Risk Factor Surveillance System (BRFSS) data show that approximately 17 percent of New Jersey adults report binge drinking, defined as consuming four or more drinks (women) or five or more drinks (men) on a single occasion within the past month.

Is Alcoholism Genetic?

The question of hereditary risk is one of the most frequently asked about alcohol addiction. Research conducted through twin studies, adoption studies, and genome-wide association studies has established that genetic factors in alcoholism are significant but not deterministic.

The NIAAA states that no single gene causes alcohol use disorder. Instead, multiple genes — each contributing a small amount of risk — interact with environmental factors to influence vulnerability. Specific genes affecting alcohol metabolism (such as those encoding alcohol dehydrogenase, or ADH, and aldehyde dehydrogenase, or ALDH, enzymes) have been identified as protective or risk-increasing factors in certain populations. Variants of the ALDH2 gene common in East Asian populations, for example, produce an unpleasant flushing reaction when alcohol is consumed, which is associated with lower rates of AUD.

Having a parent or close relative with alcohol use disorder roughly doubles or triples the risk of developing the condition, according to research published in Alcohol Research: Current Reviews. However, many individuals with a strong family history never develop AUD, and many people without a family history do. Genetic predisposition creates vulnerability, but the development of AUD requires the interaction of that predisposition with environmental triggers and individual behavior patterns.

Alcohol Rehab: What Treatment Looks Like

Treatment for alcohol use disorder follows a stepped model, with the appropriate level of care determined by the severity of the disorder, co-occurring conditions, prior treatment history, and individual circumstances. The American Society of Addiction Medicine (ASAM) criteria provide the framework that most New Jersey treatment providers use for placement decisions.

The typical treatment pathway includes:

Medical detox (for individuals with physical dependence) — Medically supervised withdrawal management, typically lasting 3 to 7 days. This is the critical first step for people at risk of severe withdrawal symptoms. Not everyone with AUD requires medical detox — individuals with mild AUD who do not have physical dependence may be able to begin treatment at the outpatient level.

Inpatient or residential treatment — 24-hour care in a structured environment, typically lasting 30 to 90 days. Includes individual and group therapy, psychoeducation, and recovery planning. Inpatient treatment is generally recommended for individuals with severe AUD, multiple failed outpatient attempts, unstable living environments, or co-occurring mental health conditions that complicate treatment.

Partial hospitalization (PHP) and intensive outpatient (IOP) — Step-down levels of care that provide structured therapy while allowing the individual to live at home or in a sober living environment. PHP typically involves 5 to 6 hours per day, 5 days per week. IOP involves 3 to 4 hours per day, 3 to 5 days per week. These levels of care are appropriate for individuals stepping down from inpatient treatment or for those whose AUD severity does not require residential care.

Outpatient treatment — Individual therapy, group therapy, or medication management on a less intensive schedule. Outpatient treatment may be the appropriate starting point for individuals with mild to moderate AUD and stable living situations.

For a detailed overview of what the alcohol rehab process involves, including what happens during intake, what a typical day looks like, and how long programs last, see the dedicated spoke page. For individuals without insurance or with limited financial resources, New Jersey offers state-funded treatment through DMHAS and county-based programs — see the guide to free and low-cost rehab in NJ.

Alcohol Withdrawal: Symptoms and Medical Management

Alcohol withdrawal is a medical condition that can range from mild discomfort to a life-threatening emergency. This distinction is critical: unlike opioid withdrawal, which is rarely fatal, severe alcohol withdrawal can kill.

Alcohol withdrawal occurs when a person who has been drinking heavily and consistently reduces or stops alcohol intake. The brain, having adapted to the constant presence of a central nervous system depressant, becomes hyperexcitable when that depressant is removed. The neurotransmitter GABA (gamma-aminobutyric acid), which alcohol enhances, becomes underactive, while glutamate, an excitatory neurotransmitter that alcohol suppresses, becomes overactive. This imbalance produces the characteristic symptoms of withdrawal.

Withdrawal Timeline

  • 6 to 12 hours after last drink: Anxiety, tremors, headache, nausea, insomnia, sweating, elevated heart rate.
  • 12 to 24 hours: Possible alcohol hallucinosis — visual, auditory, or tactile hallucinations. The individual is typically aware that the hallucinations are not real (distinguishing this from delirium).
  • 24 to 48 hours: Risk of withdrawal seizures, which occur in an estimated 3 to 5 percent of individuals undergoing alcohol withdrawal, according to the New England Journal of Medicine. Seizures can occur without prior warning symptoms and are typically generalized tonic-clonic seizures.
  • 48 to 72 hours (and beyond): Risk of delirium tremens (DTs) — the most severe form of alcohol withdrawal, characterized by confusion, agitation, hallucinations, fever, and autonomic instability. DTs occur in an estimated 3 to 5 percent of hospitalized patients undergoing withdrawal and carry a mortality rate of up to 5 percent even with treatment.

Delirium tremens (DTs): A severe, potentially fatal form of alcohol withdrawal characterized by sudden confusion, rapid heartbeat, fever, profuse sweating, and hallucinations. DTs typically develop 48 to 72 hours after the last drink and require immediate medical intervention, usually in an intensive care unit. Risk factors include a history of prolonged heavy drinking (typically 10 or more years), prior episodes of withdrawal or DTs, concurrent illness or infection, older age, and abnormal liver function.

The CIWA Protocol

The Clinical Institute Withdrawal Assessment for Alcohol (CIWA-Ar) is the standard clinical tool used to assess the severity of alcohol withdrawal. The CIWA-Ar scores 10 withdrawal symptoms — including nausea, tremor, sweating, anxiety, agitation, and sensory disturbances — on a scale from 0 to 67. Scores guide treatment decisions:

  • Score below 10: Mild withdrawal. May not require pharmacological treatment. Monitoring and supportive care.
  • Score 10 to 18: Moderate withdrawal. Medication is typically indicated.
  • Score above 18: Severe withdrawal. Aggressive pharmacological intervention and close monitoring required.

Symptom-triggered dosing based on CIWA-Ar scores allows clinicians to titrate medication to the individual’s actual symptom severity, which research has shown results in lower total medication doses and shorter treatment durations compared to fixed-schedule dosing.

Medical Management

The standard pharmacological approach to alcohol withdrawal uses benzodiazepines (such as chlordiazepoxide/Librium, diazepam/Valium, or lorazepam/Ativan), which address the same neurotransmitter systems disrupted by alcohol cessation. Dosing may follow a fixed schedule or a symptom-triggered protocol guided by CIWA-Ar scores.

Additional medications may include:

  • Anticonvulsants (carbamazepine/Tegretol, gabapentin/Neurontin) — Used in some protocols, particularly for mild to moderate withdrawal or as adjuncts to benzodiazepines.
  • Thiamine (vitamin B1) — Administered to prevent Wernicke-Korsakoff syndrome, a serious neurological condition caused by thiamine deficiency common in chronic heavy drinkers. Wernicke’s encephalopathy presents with confusion, ataxia, and eye movement abnormalities; if untreated, it can progress to Korsakoff’s syndrome, characterized by severe memory impairment.
  • Electrolyte and fluid management — Critical in severe withdrawal cases. Magnesium, potassium, and phosphate levels are monitored and repleted as needed.
  • Folate supplementation — Folate deficiency is common in chronic heavy drinkers and is routinely supplemented during withdrawal treatment.

Because of the seizure and DT risk, alcohol detox should always be conducted under medical supervision. Attempting to stop drinking abruptly after prolonged heavy use without medical oversight is dangerous and potentially fatal.

Health Consequences of Alcohol Addiction

Chronic heavy alcohol use causes damage across nearly every organ system. The relationship between alcohol and disease is dose-dependent: the more a person drinks and the longer the pattern continues, the greater the risk.

Liver disease is the most well-known consequence. Alcohol-related liver disease progresses through three stages: fatty liver (steatosis), alcoholic hepatitis, and cirrhosis. According to the NIAAA, cirrhosis was among the top 12 causes of death in the United States in 2021. Fatty liver is reversible with abstinence. Alcoholic hepatitis, an inflammatory condition, can range from mild to life-threatening. Cirrhosis — the replacement of functional liver tissue with scar tissue — is largely irreversible, though abstinence can halt progression and improve survival. For a detailed overview, see the guide to alcohol-related liver damage.

Cardiovascular effects include cardiomyopathy (weakening of the heart muscle), arrhythmias (particularly atrial fibrillation), and elevated blood pressure. While low levels of alcohol consumption have been associated with some cardiovascular benefits in older research, more recent studies — including a large-scale analysis published in The Lancet — have concluded that the safest level of alcohol consumption for overall health is zero.

Neurological effects include cognitive impairment, peripheral neuropathy (numbness and tingling in the extremities), and Wernicke-Korsakoff syndrome. Chronic alcohol use is associated with measurable brain volume loss, particularly in the prefrontal cortex and cerebellum. Some cognitive recovery is possible with sustained abstinence, though the degree of recovery depends on the duration and severity of the drinking history.

Cancer risk is increased for several cancers: the WHO’s International Agency for Research on Cancer (IARC) classifies alcohol as a Group 1 carcinogen, with established causal links to cancers of the mouth, throat, esophagus, liver, colon, rectum, and breast. The NIAAA reports that even moderate drinking — defined as one drink per day for women and two for men — is associated with a modestly increased risk of breast cancer.

Gastrointestinal effects include gastritis, pancreatitis (both acute and chronic), and esophageal varices in patients with cirrhosis. Chronic pancreatitis caused by heavy alcohol use can lead to permanent pancreatic insufficiency requiring lifelong enzyme supplementation.

The Harm Reduction Spectrum: Moderation, Medication, and the Sinclair Method

Traditional alcohol treatment messaging has been built around a binary — abstinence or active drinking. The clinical and research reality is that meaningful improvement can occur along a spectrum between those endpoints, and modern pharmacotherapy has created specific pathways for patients whose goal is reduced drinking rather than complete abstinence. This is not a framing every treatment program embraces, but it is well-supported in the research base and increasingly reflected in NJ outpatient practice.

The research case for harm reduction as a legitimate endpoint. Abstinence remains the clinically recommended goal for patients with severe alcohol use disorder — particularly those with seizure history, liver disease, or cognitive impairment. But for patients with mild-to-moderate AUD, the research shows that reduction in heavy drinking days produces meaningful health improvements (liver function, cardiovascular markers, cognitive function, relationship functioning) even when total abstinence is not achieved. NIAAA’s “rethinking drinking” framework and multiple population-level studies support reduction-focused goals as clinically valid intermediate outcomes.

Naltrexone and the Sinclair Method — the pharmacological approach to moderation. Naltrexone, FDA-approved for AUD, reduces the rewarding effect of alcohol by blocking the brain’s endogenous opioid response to drinking. Traditional use involves daily dosing aimed at supporting abstinence. The Sinclair Method (TSM) is a specific protocol developed by Finnish researcher Dr. John David Sinclair: the patient takes naltrexone one hour before drinking, then drinks normally. Over weeks to months, the absence of opioid reinforcement causes drinking to extinguish — patients often describe losing interest in alcohol even without consciously trying to quit. Multiple trials have shown TSM produces abstinence or dramatic reduction in roughly 80% of patients who complete 3-6 months of the protocol. The method is not widely taught in U.S. addiction medicine but is supported in the published literature and used by a growing number of NJ prescribers. Patients considering TSM should work with a physician familiar with the protocol — it is not interchangeable with daily-dosing naltrexone.

Extended-release naltrexone (Vivitrol) as a moderation tool. The monthly injection form of naltrexone provides similar pharmacology with less daily-adherence burden. Vivitrol can support either abstinence or reduction goals. Insurance coverage is generally available through NJ FamilyCare and commercial plans.

Moderation Management. A non-pharmacological structured approach to moderate drinking for people who have not progressed to severe AUD. MM is not appropriate for everyone — the program itself recommends that people with severe AUD pursue abstinence — but for a person with mild-to-moderate problematic drinking who has not tried reduction strategies, it offers a structured framework with meeting-based peer support. MM meetings are available online and in limited NJ locations.

When moderation is NOT appropriate. Several clinical situations require an abstinence framework regardless of patient preference:

  • History of seizure or delirium tremens during prior withdrawal
  • Pregnancy
  • Liver disease (cirrhosis, fatty liver, alcoholic hepatitis)
  • Pancreatitis or chronic GI complications related to alcohol
  • Severe AUD (6+ DSM-5 criteria) — the evidence supporting moderation is weaker in this range
  • Polysubstance use disorder including benzodiazepines or opioids
  • Significant cognitive impairment

The NJ clinician landscape. Finding a NJ provider who works within the harm reduction framework for alcohol requires specific search — most addiction-focused programs default to abstinence. Primary care physicians, certain psychiatrists, and a small number of addiction medicine specialists in NJ will prescribe naltrexone for TSM or moderation-focused treatment. The American Society of Addiction Medicine (ASAM) provider directory, filtered for NJ, is a starting point. A direct conversation with a prescribing physician about goals — “I want to reduce my drinking, not quit entirely” — is the clearest path to identifying a provider who will support that goal.

The NJ IDRC and the DUI-to-Treatment Pipeline

A substantial fraction of NJ residents who enter AUD treatment do so through the legal system rather than through self-referral — specifically through the Intoxicated Driver Resource Center (IDRC) program following a DUI conviction. Understanding how this pathway works is important for anyone navigating a DUI case and for anyone whose initial contact with the treatment system is court-ordered.

What the IDRC is. The NJ Intoxicated Driver Resource Center is a mandatory educational and assessment program for individuals convicted of driving under the influence in New Jersey. Established under N.J.S.A. 39:4-50, IDRC participation is not optional for first-offense DUI convictions — it is a statutory requirement of sentencing. The program is administered at the county level through IDRC facilities located across NJ.

The 12-hour vs. 48-hour IDRC program. For a first-offense DUI, the standard requirement is 12 hours of IDRC programming over two consecutive days. The sessions include substance use education, a structured assessment, and a review of the legal, health, and social consequences of continued impaired driving. For second-offense DUI, the requirement expands to 48 hours of IDRC programming at a more intensive residential IDRC facility. Third-offense and beyond typically includes treatment program mandates in addition to IDRC completion.

The assessment component — and how it can lead to mandated treatment. During IDRC participation, each participant completes a substance use assessment conducted by a licensed clinician. Based on the assessment, the IDRC can recommend:

  • No further treatment beyond IDRC completion (typical for lower-severity presentations)
  • Outpatient treatment for a specified duration (common for moderate presentations)
  • IOP or PHP-level treatment for more severe presentations
  • Residential treatment for severe AUD with significant functional impairment

A court-ordered treatment recommendation from IDRC carries the same enforcement as any other court order. Failure to comply can result in violation of probation, license suspension extension, or in extreme cases incarceration.

Insurance and IDRC-mandated treatment. Treatment required following IDRC assessment is generally covered by commercial insurance and NJ FamilyCare under the same parity requirements that cover voluntarily-sought treatment. Patients in this situation should not assume they need to pay out of pocket — verify benefits through the insurer’s behavioral health intake line. The treatment facility’s admissions team can usually help verify coverage.

Confidentiality considerations — the 42 CFR Part 2 question. Court-ordered treatment is not exempt from federal SUD confidentiality protections. Treatment providers are generally not permitted to share records with the court except under specific consent arrangements. However, courts often require proof of attendance and completion as a probation condition; this is typically handled through a limited Part 2 consent that permits the program to confirm attendance without disclosing clinical content. A criminal defense attorney can help structure this consent to protect the patient’s clinical record beyond what the court requires.

Strategic considerations for DUI defendants. For someone facing a DUI, voluntarily entering treatment before the court date often produces better sentencing outcomes than waiting for the IDRC assessment to mandate it. A treatment enrollment letter submitted at sentencing demonstrates good faith and can influence judicial discretion on probation terms, fines, and license suspension duration. This is a legal strategy, not just a clinical one — an attorney familiar with NJ DUI practice can advise on timing.

The relationship between DUI frequency and clinical severity. Epidemiologically, the number of lifetime DUI arrests correlates with clinical severity of AUD — a person with three DUIs is statistically more likely to have severe AUD than someone with one. This is why the IDRC system imposes increasing requirements with each subsequent offense. From a clinical perspective, a person facing their second DUI should pursue treatment with significantly more urgency than a first-offense case — the mortality curve for AUD accelerates with continued use, and repeated DUI arrests are a signal of a disease progression that is not being adequately addressed.

Resources for navigating the system. The NJ IDRC central office (operating under the Department of Health) maintains information on the program. For legal counsel, the NJ State Bar Association Lawyer Referral Service can connect DUI defendants with attorneys familiar with the intersection of criminal defense and addiction treatment.

Insurance and Cost of Alcohol Rehab in NJ

The Mental Health Parity and Addiction Equity Act (MHPAEA) and the Affordable Care Act (ACA) require most health insurance plans to cover substance use disorder treatment at the same level as other medical conditions. In practice, this means that most New Jersey residents with private insurance, Medicaid, or Medicare have coverage for alcohol addiction treatment — though the specific benefits, copays, and pre-authorization requirements vary by plan.

Medicaid (NJ FamilyCare): Covers alcohol detox, inpatient treatment, outpatient treatment, and medication-assisted treatment. New Jersey’s Medicaid expansion under the ACA significantly increased the number of residents eligible for coverage. NJ FamilyCare covers naltrexone (both oral and injectable Vivitrol), acamprosate, and disulfiram for the treatment of AUD.

Medicare: Covers inpatient detox, inpatient rehabilitation (in approved facilities), outpatient therapy, and medications. Medicare Part D covers naltrexone and other medications for AUD. Medicare Part B covers screening and behavioral counseling for alcohol misuse in primary care settings.

Private insurance: Most employer-sponsored and marketplace plans cover substance use disorder treatment. The level of coverage depends on the plan, and many plans require pre-authorization for inpatient stays beyond a certain duration. Under MHPAEA, insurers cannot impose more restrictive financial requirements or treatment limitations on substance use disorder coverage than they apply to medical/surgical benefits.

For details on Medicaid and Medicare coverage for alcohol rehab in New Jersey, see the dedicated spoke page. For individuals without insurance, state-funded treatment options are available through DMHAS county contracts — see free and low-cost rehab options.

For a broader look at how insurance interacts with addiction treatment costs across all substance types, see the insurance and cost guide.

Alcohol Addiction in Special Populations

Young Adults

Alcohol use among young adults ages 18 to 25 presents distinct challenges. This age group has the highest rates of binge drinking and alcohol use disorder nationally, according to NSDUH data. College environments, social norms around drinking, and the neurological reality that the prefrontal cortex — responsible for impulse control and decision-making — does not fully mature until approximately age 25 all contribute to elevated risk.

In New Jersey, the state’s dense concentration of colleges and universities — including Rutgers University, Montclair State University, Rowan University, and numerous community colleges — creates environments where heavy episodic drinking is culturally normalized. College-based intervention programs such as BASICS (Brief Alcohol Screening and Intervention for College Students) have been implemented at several NJ institutions.

Alcohol Abuse vs. Drug Abuse

The comparison between alcohol addiction and drug addiction is often framed as a distinction, but the clinical reality is more nuanced. Alcohol is a drug — a central nervous system depressant with significant addictive potential. The cultural normalization of alcohol use means that problematic drinking is often identified later in its progression than illicit drug use, which tends to trigger earlier intervention due to legal and social consequences.

Addiction in Media and Culture

Cultural portrayals of addiction in media shape public perception in ways that affect both stigma and treatment-seeking behavior. Film and television depictions of alcoholism range from comedic minimization to dramatic exaggeration, and neither extreme reflects the clinical reality of alcohol use disorder as a chronic, treatable medical condition.

Relapse and Long-Term Recovery

Alcohol relapse rates are consistent with those of other chronic conditions. NIDA estimates that 40 to 60 percent of individuals treated for substance use disorders experience relapse, a rate comparable to relapse for hypertension, asthma, and diabetes. Relapse is not a sign that treatment has failed — it is an indication that the treatment or recovery plan needs adjustment.

Several factors are associated with lower relapse risk:

  • Engagement in continuing care (outpatient therapy, support groups) after completing initial treatment
  • Use of FDA-approved medications for AUD (detailed below)
  • Participation in mutual aid groups such as AA, SMART Recovery, or Women for Sobriety
  • Stable housing, employment, and supportive relationships
  • Management of co-occurring mental health conditions, particularly depression and anxiety

FDA-Approved Medications for AUD

Three medications are currently FDA-approved for the treatment of alcohol use disorder. Despite strong evidence supporting their use, they remain significantly underutilized — SAMHSA data indicate that fewer than 10 percent of individuals with AUD who could benefit from these medications actually receive them.

Naltrexone (ReVia, Vivitrol): An opioid antagonist that reduces the reinforcing effects of alcohol — meaning it makes drinking less pleasurable by blocking the endorphin release that alcohol triggers. Available as a daily oral tablet (ReVia, 50 mg) or a monthly intramuscular injection (Vivitrol, 380 mg). Does not require abstinence before initiation — it can be started while a person is still drinking, which is a practical advantage. The COMBINE study, a large NIAAA-funded trial published in JAMA, found that naltrexone combined with medical management was effective in reducing heavy drinking days.

Acamprosate (Campral): Helps restore the balance of excitatory (glutamate) and inhibitory (GABA) neurotransmitter systems disrupted by chronic alcohol use. Most effective for individuals who have already achieved initial abstinence and want to maintain it. Taken as an oral tablet (333 mg) three times daily. Acamprosate does not interact with alcohol if a person does drink, which differentiates it from disulfiram. It is excreted by the kidneys and should not be used in patients with severe renal impairment.

Disulfiram (Antabuse): Creates an unpleasant physical reaction (nausea, flushing, vomiting, headache, rapid heartbeat) if alcohol is consumed while taking the medication, through inhibition of the aldehyde dehydrogenase enzyme. Functions as a deterrent rather than treating the underlying neurobiology. Requires commitment from the patient, as it can simply be stopped. Disulfiram is most effective in supervised administration settings — for example, when a family member or clinician observes the daily dose. The disulfiram-alcohol reaction can be severe and, in rare cases, dangerous, so patients must be informed of all potential sources of alcohol exposure, including mouthwash, cooking wine, and certain medications.

Long-term recovery from alcohol addiction is achievable. It requires ongoing effort, adaptable support systems, and an honest recognition that alcohol use disorder is a chronic condition that benefits from continuing management — much like any other chronic disease.

For information on the full range of treatment types available for substance use disorders in New Jersey, see the treatment types pillar page.

Topics in This Guide

Looking for treatment options in your area? We can help point you in the right direction. (888) 699-0742 — or request a callback.